Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Cancer --- Hospitals --- Treatment. --- Prospective payment. --- Hospital prospective payment --- Hospital prospective reimbursement --- Medicare hospital prospective payment --- Payment, Hospital prospective --- PPS (Medical care) --- Prospective payment, Hospital --- Prospective pricing, Hospital --- Prospective reimbursement, Hospital --- Reimbursement, Hospital prospective --- Diagnosis related groups --- Hospitalization insurance --- Cancer therapy --- Cancer treatment --- Prospective reimbursement --- Rates --- Therapy

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

"Consumer-Directed" Health Plans (CDHPs) combine high deductibles with personal medical accounts and are intended to reduce health care spending through greater patient cost sharing. Prior research shows that CDHPs reduce spending in the first year. However, there is little research on the impact of CDHPs over the longer term. We add to this literature by using data from 13 million individuals in 54 large US firms to estimate the effects of a firm offering CDHPs on health care spending up to three years post offer. We use a difference-in-differences analysis and to further strengthen identification, we balance observables within firm, over time by developing weights through a machine learning algorithm. We find that spending is reduced for those in firms offering CDHPs in all three years post. The reductions are driven by spending decreases in outpatient care and pharmaceuticals, with no evidence of increases in emergency department or inpatient care.

Zonder onderwerpscode: economie

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

"Consumer-Directed" Health Plans (CDHPs) combine high deductibles with personal medical accounts and are intended to reduce health care spending through greater patient cost sharing. Prior research shows that CDHPs reduce spending in the first year. However, there is little research on the impact of CDHPs over the longer term. We add to this literature by using data from 13 million individuals in 54 large US firms to estimate the effects of a firm offering CDHPs on health care spending up to three years post offer. We use a difference-in-differences analysis and to further strengthen identification, we balance observables within firm, over time by developing weights through a machine learning algorithm. We find that spending is reduced for those in firms offering CDHPs in all three years post. The reductions are driven by spending decreases in outpatient care and pharmaceuticals, with no evidence of increases in emergency department or inpatient care.